Skip to main content

HEAL-IST IDE Trial

Active, not recruiting · Not applicable · NCT05280093

Conditions: Inappropriate Sinus Tachycardia

At a glance

Research payments reported, 2025
$366,679
U.S. investigators named
23
Sites paid
20
Planned or actual enrollment
100

About the trial

Sponsor
AtriCure, Inc.
Tested
AtriCure ISOLATOR Synergy Surgical Ablation System (device)
Dates
Started 2022-05-31; completion 2028-02
Results posted
Not yet

Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality of life, lacking effective treatment options or systematic clinical evidence to support a therapy. The primary objective of this clinical trial is to evaluate the safety and effectiveness of a hybrid sinus node sparing ablation procedure for the treatment of symptomatic drug refractory or drug intolerant IST.

From ClinicalTrials.gov, last updated 2026-11-05. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Atricure, Inc. reported $366,679 in research payments for this study in 2025 (148 payments).

Products named: Isolator Surgical Ablation System

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.